文献速递泌尿男性生殖肿瘤

循环肿瘤DNA基因组与前列腺癌阿比特龙和恩扎卢胺耐药相关

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
PubMed 文献 · Cancer Discov · 2018-01-24

该研究将202例未经治疗的转移性去势抵抗性前列腺癌患者随机分配至阿比特龙或恩扎卢胺组,治疗前进行血浆游离DNA全外显子及72基因深度靶向测序。两种药物进展时间相似,BRCA2和ATM缺陷与不良临床结局独立相关,TP53体细胞改变亦与快速耐药独立相关,AR基因结构重排截短配体结合域见于部分原发耐药患者。

要点

  • BRCA2和ATM缺陷与mCRPC患者AR靶向治疗不良结局独立相关
  • TP53体细胞改变与快速耐药独立相关
  • AR基因截短配体结合域的结构重排见于部分原发耐药患者

核心结论

  • 血浆ctDNA基因组分析可识别mCRPC患者对一线AR靶向治疗的原发耐药驱动因素。
  • BRCA2、ATM缺陷和TP53改变独立于临床预后因素和ctDNA丰度与不良结局相关。

研究设计与样本

  • 随机II期试验,202例未经治疗的mCRPC患者随机接受阿比特龙或恩扎卢胺治疗。
  • 治疗前采集血浆cfDNA进行全外显子测序和72基因深度靶向测序。

主要发现

  • 阿比特龙与恩扎卢胺的至进展时间相似。
  • BRCA2和ATM缺陷与不良临床结局独立相关。
  • TP53体细胞改变与快速耐药独立相关。
  • AR扩增检测未优于标准预后生物标志物。
  • AR基因截短配体结合域的结构重排见于部分原发耐药患者。

临床怎么用

  • 液体活检分析可指导临床实践中AR靶向治疗的使用。
  • 治疗前ctDNA检测BRCA2、ATM、TP53及AR结构重排有助于识别原发耐药高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary resistance to androgen receptor (AR)-directed therapies in metastatic castration-resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 patients with treatment-naïve mCRPC to abiraterone or enzalutamide and performed whole-exome and deep targeted 72-gene sequencing of plasma cell-free DNA prior to therapy. For these agents, which have never been directly compared, time to progression was similar. Defects in BRCA2 and ATM were strongly associated with poor clinical outcomes independently of clinical prognostic factors and circulating tumor DNA abundance. Somatic alterations in TP53, previously linked to reduced tumor dependency on AR signaling, were also independently associated with rapid resistance. Although detection of AR amplifications did not outperform standard prognostic biomarkers, AR gene structural rearrangements truncating the ligand binding domain were identified in several patients with primary resistance. These findings establish genomic drivers of resistance to first-line AR-directed therapy in mCRPC and identify potential minimally invasive biomarkers.Significance: Leveraging plasma specimens collected in a large randomized phase II trial, we report the relative impact of common circulating tumor DNA alterations on patient response to the most widely used therapies for advanced prostate cancer. Our findings suggest that liquid biopsy analysis can guide the use of AR-targeted therapy in general practice. Cancer Discov; 8(4); 444-57. ©2018 AACR.See related commentary by Jayaram et al., p. 392This article is highlighted in the In This Issue feature, p. 371.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Annala M, Vandekerkhove G, Khalaf D, et al. Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discov. 2018. PMID: 29367197. doi:10.1158/2159-8290.CD-17-0937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。